NCT04468568View on ClinicalTrials.gov

In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

January 31, 2020

Study Completion Date

April 1, 2022

Conditions
MyelomeningoceleTerbutaline Adverse ReactionPregnancy; Malformation Central Nervous System
Interventions
DRUG

Atosiban

Atosiban intravenous. Dose: attack of 6.75 mg, and maintenance of 300 mcg / min for 3 hours, and 100 mcg / min for 21 hours.

DRUG

Terbutaline

Terbutaline intravenous. Dose: 2.5 mg in 500 mL saline, infusion rate of 30 mL / hr (150 mcg / h) during the surgery and for 24 hours.

Trial Locations (1)

Unknown

Faculdade de Medicina da Universidade de São Paulo, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT04468568 - In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline | Biotech Hunter | Biotech Hunter